yahoo.comSEP 171 min read$RMD

This Analyst Just Upgraded ResMed Stock. Here's Why.

Analysts rate ResMed (RMD) stock as 'Moderate Buy' with price targets up to $320, suggesting 40% upside from current levels, according to Barchart.

Original reporting

yahoo.com

Published Sep 17, 2026, 7:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 17, 2026, 7:14 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

This Analyst Just Upgraded ResMed Stock. Here's Why. — source image — Source · yahoo.com

Decision brief

The 30-second read

$RMDBullishMed

Why it matters

Analyst upgrade signals improved growth expectations, potentially prompting short‑term buying.

Market read

The upgrade may generate modest price movement in RMD and influence related healthcare stocks.

What to watch

No new earnings or product data accompanies the upgrade.

Relevance 7/10Novelty 6/10Timing: today

Background

ResMed is a medical‑device company focused on sleep apnea solutions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RMDBullishMedium confidence

Context

Analyst upgrade to Moderate Buy with price targets up to $320, indicating potential 40% upside.

Expected impact

Potential price increase of 5-10% over the next weeks.

Evidence & confidence

Upgrade and high price target suggest improved outlook, but no concrete financial data released.

Market effects

Sector

May lift other sleep‑technology stocks.

Regional

US healthcare sector could see modest uplift.

Global

Limited to investors tracking medical device equities.

Counterpoint

What could challenge this read

Upgrade could be premature if earnings miss expectations.

Key entities

Company
ResMed Inc.
Provider of cloud‑connected medical devices for sleep disorders.
Data Provider
Barchart
Aggregates analyst ratings and price targets.

Read at source ← All news

SEP 16

$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min

SEP 16

$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min

SEP 15

$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min

SEP 15

$RMDHigh

ResMed stock jumps 3% on RBC Capital upgrade to Outperform

ResMed Inc (RMD) shares rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. The upgrade cited ResMed's leadership in sleep apnea devices, strong Q4 growth, and FDA recall of a competitor's device. RBC expects high single-digit EPS growth over three years.

investing.com1 min

SEP 14

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min